{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:07:31Z","timestamp":1772165251576,"version":"3.50.1"},"reference-count":84,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10,15]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>This trial evaluated frontline VR-CAP and R-CHOP therapy for patients with centrally confirmed non-GCB DLBCL. There was no significant improvement in response rates or long-term outcomes with VR-CAP vs R-CHOP in previously untreated non-GCB DLBCL.<\/jats:p>","DOI":"10.1182\/blood-2015-03-632430","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T22:39:09Z","timestamp":1438382349000},"page":"1893-1901","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL"],"prefix":"10.1182","volume":"126","author":[{"given":"Fritz","family":"Offner","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Ghent, Ghent, Belgium;"}]},{"given":"Olga","family":"Samoilova","sequence":"additional","affiliation":[{"name":"Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation;"}]},{"given":"Evgenii","family":"Osmanov","sequence":"additional","affiliation":[{"name":"N.N. Blokhin Cancer Research Center, Russian Academy of National Sciences, Moscow, Russian Federation;"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[{"name":"National Cancer Center, Goyang Gyeonggi, Republic of Korea;"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}]},{"given":"Jo\u00e3o","family":"Raposo","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia, Santa Maria Hospital, Lisbon, Portugal;"}]},{"given":"Viacheslav","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Medical Scientific Radiology Center, Obninsk, Russian Federation;"}]},{"given":"Deborah","family":"Ricci","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ;"}]},{"given":"Shalini","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}]},{"given":"Eugene","family":"Zhu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ;"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium; and"}]},{"given":"Christopher","family":"Enny","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ;"}]},{"given":"Aleksandra","family":"Rizo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ;"}]},{"given":"Burhan","family":"Ferhanoglu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Koc University, Istanbul, Turkey"}]}],"member":"234","reference":[{"issue":"3","key":"2019111901404423800_B1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/107327481201900305","article-title":"Diffuse large B-cell lymphoma: current strategies and future directions.","volume":"19","author":"Cultrera","year":"2012","journal-title":"Cancer Contr"},{"issue":"6","key":"2019111901404423800_B2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/14656566.7.6.733","article-title":"Novel treatment strategies for aggressive non-Hodgkin\u2019s lymphoma.","volume":"7","author":"Fayad","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"6769","key":"2019111901404423800_B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"22","key":"2019111901404423800_B4","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas.","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111901404423800_B5","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1200\/JCO.2005.05.012","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma.","volume":"23","author":"Lossos","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111901404423800_B6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5507\/bp.2012.085","article-title":"Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL).","volume":"157","author":"Nedomova","year":"2013","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"25","key":"2019111901404423800_B7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111901404423800_B8","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.","volume":"106","author":"Bea","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111901404423800_B9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"issue":"17","key":"2019111901404423800_B10","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2019111901404423800_B11","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111901404423800_B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111901404423800_B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111901404423800_B14","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"31","key":"2019111901404423800_B15","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study.","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111901404423800_B16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies.","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2019111901404423800_B17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"2019111901404423800_B18"},{"issue":"3","key":"2019111901404423800_B19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"issue":"28","key":"2019111901404423800_B20","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.","volume":"26","author":"Fu","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111901404423800_B21","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1182\/blood-2008-02-136374","article-title":"Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.","volume":"111","author":"Malumbres","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111901404423800_B22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","article-title":"LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.","volume":"26","author":"Natkunam","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111901404423800_B23","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1182\/blood-2008-02-137372","article-title":"Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.","volume":"112","author":"Rimsza","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111901404423800_B24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"47","key":"2019111901404423800_B25","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1073\/pnas.0907511106","article-title":"Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma [published correction appears in Proc Natl Acad Sci USA. 2013;110(7):2677].","volume":"106","author":"Hailfinger","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111901404423800_B26","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma.","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"issue":"7089","key":"2019111901404423800_B27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer.","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"issue":"13","key":"2019111901404423800_B28","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-07-4470","article-title":"Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-kappaB subunits in head and neck cancer.","volume":"14","author":"Allen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111901404423800_B29","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1158\/1078-0432.CCR-08-0839","article-title":"Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.","volume":"14","author":"Ayala","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111901404423800_B30","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.","volume":"61","author":"Cusack","year":"2001","journal-title":"Cancer Res"},{"issue":"19","key":"2019111901404423800_B31","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma.","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111901404423800_B32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10428194.2013.806799","article-title":"Bortezomib inhibits proteasomal degradation of I\u03baB\u03b1 and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.","volume":"55","author":"Bu","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111901404423800_B33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111901404423800_B34","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3109\/10428194.2012.656629","article-title":"Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.","volume":"53","author":"Elstrom","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 4","key":"2019111901404423800_B35","first-page":"Abstract 135","article-title":"All B lymphoma subtypes do not share similar outcome after frontline R-CHOP plus bortezomib treatment: A randomized phase 2 trial from the Groupe d\u2019etude des lymphomes de l\u2019adulte (GELA).","volume":"19","author":"Mounier","year":"2008","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111901404423800_B36","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111901404423800_B37"},{"issue":"5","key":"2019111901404423800_B38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111901404423800_B39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111901404423800_B40","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/ijc.23397","article-title":"Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues.","volume":"122","author":"Chen","year":"2008","journal-title":"Int J Cancer"},{"issue":"5","key":"2019111901404423800_B41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111901404423800_B42"},{"issue":"12","key":"2019111901404423800_B43","first-page":"1375","article-title":"Randomized phase II clinical trials.","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"issue":"10","key":"2019111901404423800_B44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9880","key":"2019111901404423800_B45","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2019111901404423800_B46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111901404423800_B47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111901404423800_B48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma.","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2019111901404423800_B49","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"issue":"24","key":"2019111901404423800_B50","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111901404423800_B51","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","article-title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.","volume":"99","author":"Seymour","year":"2014","journal-title":"Haematologica"},{"issue":"18","key":"2019111901404423800_B52","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"117","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111901404423800_B53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","article-title":"Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.","volume":"14","author":"Read","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"2019111901404423800_B54","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2009.22.7058","article-title":"Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.","volume":"27","author":"Copie-Bergman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"2019111901404423800_B55","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","article-title":"Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte\/lymphoma study association phase III trial LNH 03-2B.","volume":"32","author":"Molina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111901404423800_B56","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3109\/10428194.2014.982645","article-title":"Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"2019111901404423800_B57","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111901404423800_B58","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood"},{"issue":"5870","key":"2019111901404423800_B59","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"2","key":"2019111901404423800_B60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma.","volume":"52","author":"Young","year":"2015","journal-title":"Semin Hematol"},{"key":"2019111901404423800_B61","author":"Wilson"},{"issue":"9","key":"2019111901404423800_B62","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111901404423800_B63","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1080\/10428190903165233","article-title":"Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.","volume":"50","author":"Chaiwatanatorn","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111901404423800_B64","author":"Crump"},{"issue":"9","key":"2019111901404423800_B65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00277-006-0144-y","article-title":"Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.","volume":"85","author":"Espinosa","year":"2006","journal-title":"Ann Hematol"},{"issue":"10","key":"2019111901404423800_B66","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/modpathol.3800434","article-title":"Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma.","volume":"18","author":"Hans","year":"2005","journal-title":"Mod Pathol"},{"key":"2019111901404423800_B67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6150-2-8","article-title":"Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.","volume":"2","author":"Li","year":"2007","journal-title":"Biol Direct"},{"issue":"5","key":"2019111901404423800_B68","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/modpathol.2010.43","article-title":"Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.","volume":"23","author":"Riihij\u00e4rvi","year":"2010","journal-title":"Mod Pathol"},{"issue":"3","key":"2019111901404423800_B69","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/modpathol.3800738","article-title":"PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma.","volume":"20","author":"Schaffel","year":"2007","journal-title":"Mod Pathol"},{"issue":"1","key":"2019111901404423800_B70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/embr.201337983","article-title":"The I\u03baB kinase complex in NF-\u03baB regulation and beyond.","volume":"15","author":"Hinz","year":"2014","journal-title":"EMBO Rep"},{"issue":"31","key":"2019111901404423800_B71","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2019111901404423800_B72","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-12-0217","article-title":"Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions.","volume":"18","author":"Steinhardt","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7247","key":"2019111901404423800_B73","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"1","key":"2019111901404423800_B74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-\u03baB in lymphoid malignancies.","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol Rev"},{"issue":"8","key":"2019111901404423800_B75","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas.","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111901404423800_B76","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2019111901404423800_B77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3960\/jslrt.51.7","article-title":"BCL2 and MYC dual-hit lymphoma\/leukemia.","volume":"51","author":"Tomita","year":"2011","journal-title":"J Clin Exp Hematop"},{"issue":"10","key":"2019111901404423800_B78","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3324\/haematol.11263","article-title":"High-grade B-cell lymphoma\/leukemia associated with t(14;18) and 8q24\/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis.","volume":"92","author":"Lin","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2019111901404423800_B79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"28","key":"2019111901404423800_B80","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111901404423800_B81","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"28","key":"2019111901404423800_B82","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111901404423800_B83","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2019111901404423800_B84","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1002\/cncr.25509","article-title":"Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.","volume":"116","author":"Furman","year":"2010","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/16\/1893\/1389144\/1893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/16\/1893\/1389144\/1893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:41:19Z","timestamp":1574127679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/16\/1893\/34580\/Frontline-rituximab-cyclophosphamide-doxorubicin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,15]]},"references-count":84,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-03-632430","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725690867.793521339","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,15]]}}}